BRPI0406499A - Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2 - Google Patents

Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2

Info

Publication number
BRPI0406499A
BRPI0406499A BR0406499-2A BRPI0406499A BRPI0406499A BR PI0406499 A BRPI0406499 A BR PI0406499A BR PI0406499 A BRPI0406499 A BR PI0406499A BR PI0406499 A BRPI0406499 A BR PI0406499A
Authority
BR
Brazil
Prior art keywords
patients
type
mortality
diabetes
long
Prior art date
Application number
BR0406499-2A
Other languages
English (en)
Inventor
Ralf Rosskamp
Hertzel Gerstein
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BRPI0406499A publication Critical patent/BRPI0406499A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"INSULINA DE LONGA ATUAçãO PARA REDUçãO DA MORBIDEZ E MORTALIDADE CARDIOVASCULAR EM PACIENTES PRé-DIABéTICOS E PACIENTES COM DIABETES TIPO 2". A presente invenção refere-se a um método para redução da morbidez e mortalidade cardiovascular em uma população de paciente de Diabetes Tipo 2 ou pré-diabética. O método compreende administrar uma dosagem eficaz de uma insulina de longa atuação, preferivelmente, insulina glargina, a um paciente de Diabetes Tipo 2 ou pré-diabético.
BR0406499-2A 2003-01-14 2004-01-14 Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2 BRPI0406499A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43994103P 2003-01-14 2003-01-14
PCT/US2004/000879 WO2004064862A1 (en) 2003-01-14 2004-01-14 Long acting insulin for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes

Publications (1)

Publication Number Publication Date
BRPI0406499A true BRPI0406499A (pt) 2005-12-06

Family

ID=23746761

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406499-2A BRPI0406499A (pt) 2003-01-14 2004-01-14 Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2

Country Status (16)

Country Link
US (4) US7405196B2 (pt)
EP (2) EP2596800B1 (pt)
JP (1) JP5389325B2 (pt)
AU (2) AU2004206829B2 (pt)
BR (1) BRPI0406499A (pt)
CA (1) CA2512820C (pt)
CY (1) CY1118738T1 (pt)
DK (1) DK2596800T3 (pt)
ES (1) ES2604359T3 (pt)
GB (1) GB0309154D0 (pt)
HU (1) HUE031892T2 (pt)
IL (3) IL169697A (pt)
MX (1) MXPA05007470A (pt)
PT (1) PT2596800T (pt)
SI (1) SI2596800T1 (pt)
WO (1) WO2004064862A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
WO2005012346A1 (en) * 2003-07-25 2005-02-10 Conjuchem, Inc. Long lasting insulin derivatives and methods thereof
JP5078014B2 (ja) 2004-08-20 2012-11-21 マンカインド コーポレイション ジケトピペラジン合成の触媒反応
MX2007002189A (es) 2004-08-23 2008-01-11 Mannkind Corp Sales de dicetopiperazina, sales de dicetomorfolina o sales de dicetodioxano para suministro de farmacos.
US7803404B2 (en) 2005-09-14 2010-09-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
IN2015DN00888A (pt) 2006-02-22 2015-07-10 Mannkind Corp
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101933816B1 (ko) 2008-06-13 2019-03-29 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
WO2009155581A1 (en) 2008-06-20 2009-12-23 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
KR101285520B1 (ko) 2008-12-23 2013-07-17 에프. 호프만-라 로슈 아게 만성 질병을 가진 환자의 진단 또는 치료 지원을 위한 구조화된 테스팅 방법 및 그 디바이스
US10456036B2 (en) 2008-12-23 2019-10-29 Roche Diabetes Care, Inc. Structured tailoring
US9918635B2 (en) 2008-12-23 2018-03-20 Roche Diabetes Care, Inc. Systems and methods for optimizing insulin dosage
US10437962B2 (en) 2008-12-23 2019-10-08 Roche Diabetes Care Inc Status reporting of a structured collection procedure
US20120011125A1 (en) 2008-12-23 2012-01-12 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US8849458B2 (en) * 2008-12-23 2014-09-30 Roche Diagnostics Operations, Inc. Collection device with selective display of test results, method and computer program product thereof
US9117015B2 (en) 2008-12-23 2015-08-25 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
BRPI1013154B1 (pt) 2009-06-12 2020-04-07 Mannkind Corp Micropartículas de dicetopiperazina com áreas de superfície específicas definidas, pó seco compreendendo as referidas micropartículas, método para formação das referidasmicropartículas e formação de micropartículas de fumaril diacetopiperazina, uso das referidas micropartículas e sistema de inalação
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
US20120173151A1 (en) 2010-12-29 2012-07-05 Roche Diagnostics Operations, Inc. Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US8755938B2 (en) 2011-05-13 2014-06-17 Roche Diagnostics Operations, Inc. Systems and methods for handling unacceptable values in structured collection protocols
US8766803B2 (en) 2011-05-13 2014-07-01 Roche Diagnostics Operations, Inc. Dynamic data collection
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
IN2014DN03093A (pt) 2011-10-24 2015-05-15 Mannkind Corp
WO2013079691A1 (en) * 2011-12-01 2013-06-06 Sanofi Insulin glargine versus metformin for the first-line treatment of early type 2 diabetes
CA2865823A1 (en) * 2012-03-28 2013-10-03 Sanofi Basal insulin therapy
SG10201605800UA (en) 2012-07-12 2016-09-29 Mannkind Corp Dry powder drug delivery system and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
KR102499439B1 (ko) 2013-03-15 2023-02-13 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
DK2983697T3 (en) 2013-04-03 2019-02-25 Sanofi Sa TREATMENT OF DIABETES MELLITUS WITH LONG-EFFECTIVE FORMULATIONS OF INSULIN
CA2918369C (en) 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2016001185A1 (en) * 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA2970200A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20180369342A1 (en) * 2015-12-23 2018-12-27 Sanofi-Aventis Deutschland Gmbh Cardiac metabolic effect of lantus
CN110099719A (zh) * 2016-11-28 2019-08-06 诺和诺德股份有限公司 用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
CN110022935A (zh) 2016-11-28 2019-07-16 诺和诺德股份有限公司 用于心血管病况的德谷胰岛素
US11366189B2 (en) * 2020-09-25 2022-06-21 Uih America, Inc. Systems and methods for magnetic resonance imaging

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354331A (en) 1992-07-15 1994-10-11 Schachar Ronald A Treatment of presbyopia and other eye disorders
DE69826286T2 (de) * 1997-06-27 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Derivate mit einem aromatischen ring
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
EP1284723A4 (en) * 2000-04-19 2004-06-30 Borody Thomas J COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA
JP4236464B2 (ja) * 2000-10-26 2009-03-11 フォーリナー ラボラトリーズ アイルランド リミテッド 内皮機能不全治療用のフェノフィブラートと補酵素ｑ１０との組み合わせ

Also Published As

Publication number Publication date
AU2010202738A1 (en) 2010-07-22
CA2512820A1 (en) 2004-08-05
JP2006515625A (ja) 2006-06-01
AU2004206829A1 (en) 2004-08-05
ES2604359T3 (es) 2017-03-06
IL197739A0 (en) 2011-08-01
HUE031892T2 (en) 2017-08-28
WO2004064862A1 (en) 2004-08-05
IL208525A0 (en) 2010-12-30
EP1589991A1 (en) 2005-11-02
DK2596800T3 (en) 2016-12-12
IL169697A0 (en) 2007-07-04
MXPA05007470A (es) 2005-09-21
SI2596800T1 (sl) 2017-04-26
IL169697A (en) 2011-06-30
EP2596800B1 (en) 2016-08-24
JP5389325B2 (ja) 2014-01-15
PT2596800T (pt) 2016-12-02
US20080287343A1 (en) 2008-11-20
GB0309154D0 (en) 2003-05-28
US20130012433A1 (en) 2013-01-10
AU2004206829B2 (en) 2010-04-08
US20110281793A1 (en) 2011-11-17
EP2596800A1 (en) 2013-05-29
US8809270B2 (en) 2014-08-19
AU2010202738B2 (en) 2013-12-05
CY1118738T1 (el) 2017-07-12
CA2512820C (en) 2013-06-04
IL197739A (en) 2017-02-28
US20040229774A1 (en) 2004-11-18
US7405196B2 (en) 2008-07-29
US7977310B2 (en) 2011-07-12

Similar Documents

Publication Publication Date Title
BRPI0406499A (pt) Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2
BR0314799A (pt) Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico
BR9906796A (pt) Método para a administração de análogos de insulina monoméricos
MXPA05006994A (es) Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
NO20024586D0 (no) Metode og preparater for å forhindre hormoninduserte bivirkninger
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
MX2008004734A (es) Composicion rica en leucina.
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0307540A (pt) Preparação farmacêutica em forma de filme ou em forma de lâmina para administrar substâncias ativas, uso da preparação farmacêutica e processo para a administração oral de substância(s) farmaceuticamente ativa(s) dotadas de sabor amargo
HUP9803044A2 (hu) Ibuprofentartalmú készítmény
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
BRPI0518460A2 (pt) mÉtodo para tratar emergÊncia alÉrgica em um paciente, dispositivo de distribuiÇço de droga contendo uma soluÇço de epinefrina, e, kit para tratar uma emergÊncia alÉrgia'
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
UY27186A1 (es) Formulación farmacéutica
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
WO2003090671A3 (en) Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
PL1680128T3 (pl) Heksafosforan mio-inozytolu do stosowania miejscowego
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
BRPI0410374A (pt) composição farmacêutica que compreende valsartano

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]